Biocon and Mylan Launch Fulphila (biosimilar- Pegfilgrastim) in Australia

Share this

Biocon and Mylan Launch Fulphila (biosimilar- Pegfilgrastim) in Australia


  • The companies launched Fulphila- a biosimilar referencing Neulasta (pegfilgrastim) in Australia. The biosimilar received TGA’s approval to treat cancer patients following the CT- to decrease the duration of neutropenia and to reduce the incidence of infections- as manifested by febrile neutropenia
  • The approval is based on analytical- clinical and nonclinical data which demonstrated that the Fulphila showed bio-similarity to Neulasta and no clinically meaningful differences in terms of safety and efficacy exist
  • Fulphila is the first biosimilar pegfilgrastim to be approved in the US and was successfully launched in July’2018 and has received regulatory approval in 30+ countries across the globe. The therapy is the third biosimilar to be commercialized in Australia and is available on PBS

Click here ­to­ read full press release/ article | Ref: Biocon | Image: Pinterest

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions